nach oben

Diabetologia

Erschienen in:

01.06.2006 | Article

Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation

verfasst von: L. Perségol, B. Vergès, M. Foissac, P. Gambert, L. Duvillard

Erschienen in: Diabetologia | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

In healthy normolipidaemic and normoglycaemic control subjects, HDL are able to reverse the inhibition of vasodilation that is induced by oxidised LDL. In type 2 diabetic patients, HDL are glycated and more triglyceride-rich than in control subjects. These alterations are likely to modify the capacity of HDL to reverse the inhibition of vasodilation induced by oxidised LDL.

Subjects and methods

Using rabbit aorta rings, we compared the ability of HDL from 16 type 2 diabetic patients and 13 control subjects to suppress the inhibition of vasodilation that is induced by oxidised LDL.

Results

Oxidised LDL inhibited endothelium-dependent vasodilation (maximal relaxation [Emax]=58.2±14.6 vs 99.3±5.2% for incubation without any lipoprotein, p<0.0001). HDL from control subjects significantly reduced the inhibitory effect of oxidised LDL on vasodilatation (Emax=77.6±12.9 vs 59.5±7.7%, p<0.001), whereas HDL from type 2 diabetic patients had no effect (Emax=52.4±20.4 vs 57.2±18.7%, NS). HDL triglyceride content was significantly higher in type 2 diabetic patients than in control subjects (5.3±2.2 vs 3.1±1.4%, p<0.01) and was highly inversely correlated to Emax for oxidised LDL+HDL in type 2 diabetic patients (r=−0.71, p<0.005).

Conclusions/interpretation

In type 2 diabetes mellitus, the ability of HDL to counteract the inhibition of endothelium-dependent vasorelaxation induced by oxidised LDL is impaired and is inversely correlated with HDL triglyceride content. These findings suggest that HDL are less atheroprotective in type 2 diabetic patients than in control subjects.

Biesbroeck RC, Albers JJ, Wahl PW, Weinberg CR, Bassett ML, Bierman EL (1982) Abnormal composition of high density lipoproteins in non-insulin-dependent diabetics. Diabetes 31:126–131PubMed

Taskinen MR (1992) Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes 41(Suppl 2):12–17PubMed

Bisoendial RJ, Hoving GK, Levels JHM et al (2003) Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 107:2944–2948PubMedCrossRef

Spieker LE, Sudano I, Hurlimann D et al (2002) High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105:1399–1402PubMedCrossRef

Matsuda Y, Hirata K, Inoue N et al (1993) High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation. Circ Res 72:1103–1109PubMed

Halcox JP, Schenke WH, Zalos G et al (2002) Prognostic value of coronary vascular endothelial dysfunction. Circulation 106:653–658PubMedCrossRef

Schachinger V, Britten MB, Zeiher AM (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101:1899–1906PubMed

McVeigh GE, Brennan GM, Johnston GD et al (1992) Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35:771–776PubMed

Deckert V, Perségol L, Viens L et al (1997) Inhibitors of arterial relaxation among components of human oxidized low-density lipoproteins. Cholesterol derivatives oxidized in position 7 are potent inhibitors of endothelium-dependent relaxation. Circulation 95:723–731PubMed

10.

Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) (2001) Executive summary of The Third Report of The National Cholesterol Education Program (NCEP). JAMA 285:2486–2497CrossRef

11.

Gowri MS, Van der Westhuysen DR, Bridges SR, Anderson JW (1999) Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol 19:2226–2233PubMed

12.

Jacobs M, Plane F, Bruckdorfer RK (1990) Native and oxidized low-density lipoproteins have different inhibitory effects on endothelium-derived relaxing factor in the rabbit aorta. Br J Pharmacol 100:21–26PubMed

13.

Deckert V, Brunet A, Lantoine F et al (1998) Inhibition by cholesterol oxides of NO release from human vascular endothelial cells. Arterioscler Thromb Vasc Biol 18:1054–1060PubMed

14.

Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD (1990) Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 344:160–162PubMedCrossRef

15.

Jessup W (1996) Oxidized lipoproteins and nitric oxide. Curr Opin Lipidol 7:274–280PubMedCrossRef

16.

Wever R, Stroes E, Rabelink TJ (1998) Nitric oxide and hypercholesterolemia: a matter of oxidation and reduction? Atherosclerosis 137:51–60CrossRef

17.

Blair A, Shaul PW, Yuhanna IS, Conrad PA, Smart EJ (1999) Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem 274:32512–32519PubMedCrossRef

18.

Christison JK, Rye K-A, Stocker R (1995) Exchange of oxidized cholesteryl linoleate between LDL and HDL by cholesteryl ester transfer protein. J Lipid Res 36:2017–2026PubMed

19.

Mackness MI, Arrol S, Abbott C, Durrington P (1993) Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104:129–135PubMedCrossRef

20.

Watson AD, Berliner JA, Hama SY et al (1995) Protective effect of high density lipoprotein associated paraoxonase. J Clin Invest 96:2882–2891PubMedCrossRef

21.

Watson AD, Navab M, Hama SY et al (1995) Effect of platelet-activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 95:774–782PubMedCrossRef

22.

Uittenbogaard A, Shaul PW, Yuhanna IS, Blair A, Smart EJ (2000) High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem 275:11278–11283PubMedCrossRef

23.

Drew BG, Fidge NH, Gallon-Beaumier G, Kemp BE, Kingwell BA (2004) High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc Natl Acad Sci USA 101:6999–7004PubMedCrossRef

24.

Mineo C, Yuhanna IS, Quon MJ, Shaul PW (2003) High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem 278:9142–9149PubMedCrossRef

25.

Nofer JR, van der Giet M, Tölle M et al (2004) HDL induces NO-dependent relaxation via lysophospholipid receptor S1P3. J Clin Invest 113:569–581PubMed

26.

Kuvin JT, Rämet ME, Patel AR, Pandian NG, Mendelson ME, Karas RH (2002) A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 144:165–172PubMedCrossRef

27.

Hansel B, Giral P, Nobecourt E et al (2004) Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 89:4963–4971PubMedCrossRef

28.

Nobecourt E, Jacqueminet S, Hansel B et al (2005) Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 48:529–538PubMedCrossRef

29.

Kopprasch S, Pietzsch J, Kuhlisch E, Graessler J (2003) Lack of association between serum paraoxonase 1 activities and increased oxidized low-density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus. J Clin Endocrinol Metab 88:1711–1716PubMedCrossRef

30.

Thomas MJ, Chen Q, Zabalawi M et al (2001) Is the oxidation of high-density lipoprotein lipids different than the oxidation of low-density lipoprotein lipids? Biochemistry 13:1719–1724CrossRef

31.

Curtiss LK, Bonnet DJ, Rye KA (2000) The conformation of apolipoprotein A-I in high-density lipoproteins is influenced by core lipid composition and particle size: a surface plasmon resonance study. Biochemistry 39:5712–5721PubMedCrossRef

32.

Braschi S, Coffill CR, Neville TA, Hutt DM, Sparks DL (2001) Effect of acylglyceride content on the structure and function of reconstituted high density lipoprotein particles. J Lipid Res 42:79–87PubMed

Titel: Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation
verfasst von: L. Perségol
B. Vergès
M. Foissac
P. Gambert
L. Duvillard
Publikationsdatum: 01.06.2006
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 6/2006
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-006-0244-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Aims/hypothesis

Subjects and methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2006

Intracellular amyloid-like deposits contain unprocessed pro-islet amyloid polypeptide (proIAPP) in beta cells of transgenic mice overexpressing the gene for human IAPP and transplanted human islets

Digami too?

Interferon-γ potentiates endoplasmic reticulum stress-induced death by reducing pancreatic beta cell defence mechanisms

Sex- and season-dependent differences in C-peptide levels at diagnosis of immune-mediated type 1 diabetes

Diabetic encephalopathy: a concept in need of a definition